Biocon rises on getting marketing authorization for Novel Biologic Itolizumab for Psoriasis

08 Jan 2013 Evaluate

Biocon is currently trading at Rs 303.55, up by 1.80 points or 0.60% from its previous closing of Rs 301.75 on the BSE.

The scrip opened at Rs 304.65 and has touched a high and low of Rs 305.65 and Rs 302.00 respectively. So far 60086 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 321.50 on 16-Nov-2012 and a 52 week low of Rs 208.10 on 04-Jun-2012.

Last one week high and low of the scrip stood at Rs 305.65 and Rs 286.30 respectively. The current market cap of the company is Rs 6035.00 crore.

The promoters holding in the company stood at 60.96% while Institutions and Non-Institutions held 15.41% and 23.63% respectively.

Biocon, Asia’s premier biotechnology company has received marketing authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis. Itolizumab, is a first in class therapy with a unique mechanism of action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. It is the second Novel Biologic developed by Biocon at Asia’s largest Biotech hub in Bangalore.

This approval paves the way for the launch of Biocon’s Alzumab in India, later during 2013. Alzumab is a differentiated biologic drug with a superior safety profile compared to other approved biologic therapies given its very low opportunistic infection rates. A novel biologic indicated for the treatment of moderate-to-severe Psoriasis, Alzumab will be marketed by the company’s Immunotherapy Division. Alzumab, will be manufactured and formulated as an infusion drug at Biocon’s Biopharma manufacturing facility at Biocon Park, Bangalore.

Alzumab is expected to provide a safe & effective treatment options for Psoriasis, a socially debilitating disease affecting 2-3% of Indian population. The global Psoriasis market is estimated to cross $8 billion by 2016. Itolizumab has shown promising preclinical and clinical efficacy in other auto immune diseases like RA, MS. The company aims to file a US IND in 2013 to facilitate global clinical trials in Psoriasis, RA and other indications as a subcutaneous formulation. Biocon plans to develop this molecule with a global partner for various markets across the world.

Biocon is India’s premier biotechnology company with a strategic focus on biopharmaceuticals and research services. Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×